probucol has been researched along with Chronic Illness in 8 studies
Probucol: A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).
probucol : A dithioketal that is propane-2,2-dithiol in which the hydrogens attached to both sulfur atoms are replaced by 3,5-di-tert-butyl-4-hydroxyphenyl groups. An anticholesteremic drug with antioxidant and anti-inflammatory properties, it is used to treat high levels of cholesterol in blood.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thirty-eight men with chronic coronary heart disease (CHD) aged 38 to 65 years (ten patients with attendant obliterating atherosclerosis of lower extremity vessels) were treated with the hypolipidemic drug probucol in a dose of 1000 mg/day for three months." | 7.67 | [Effect of probucol on lipid metabolism and the clinical course of ischemic heart disease and arteriosclerosis obliterans of the vessels of the lower extremities]. ( Diukov, IV; Dudaev, VA; Gorin, VV; Kliuchnikova, ZhI; Shingireĭ, MV, 1984) |
| "We investigated the effect of probucol, a lipid-lowering agent with antioxidant properties, on HCl plus ethanol-induced gastric mucosal injury and on the healing of acetic acid-induced gastric ulcers in rats." | 3.70 | Anti-ulcer effects of antioxidants: effect of probucol. ( Ishihara, M; Ito, M; Suzuki, Y, 1998) |
| "Thirty-eight men with chronic coronary heart disease (CHD) aged 38 to 65 years (ten patients with attendant obliterating atherosclerosis of lower extremity vessels) were treated with the hypolipidemic drug probucol in a dose of 1000 mg/day for three months." | 3.67 | [Effect of probucol on lipid metabolism and the clinical course of ischemic heart disease and arteriosclerosis obliterans of the vessels of the lower extremities]. ( Diukov, IV; Dudaev, VA; Gorin, VV; Kliuchnikova, ZhI; Shingireĭ, MV, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (12.50) | 18.7374 |
| 1990's | 4 (50.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Meng, CQ | 1 |
| Somers, PK | 1 |
| Hoong, LK | 1 |
| Zheng, XS | 1 |
| Ye, Z | 1 |
| Worsencroft, KJ | 1 |
| Simpson, JE | 1 |
| Hotema, MR | 1 |
| Weingarten, MD | 1 |
| MacDOnald, ML | 1 |
| Hill, RR | 1 |
| Marino, EM | 1 |
| Suen, KL | 1 |
| Luchoomun, J | 1 |
| Kunsch, C | 1 |
| Landers, LK | 1 |
| Stefanopoulos, D | 1 |
| Howard, RB | 1 |
| Sundell, CL | 1 |
| Saxena, U | 1 |
| Wasserman, MA | 1 |
| Sikorski, JA | 1 |
| Betge, S | 1 |
| Lutz, K | 1 |
| Roskos, M | 1 |
| Figulla, HR | 1 |
| Dudaev, VA | 1 |
| Gorin, VV | 1 |
| Shingireĭ, MV | 1 |
| Kliuchnikova, ZhI | 1 |
| Diukov, IV | 1 |
| Lankin, VZ | 2 |
| Revenko, VM | 2 |
| Lupanov, VP | 2 |
| Tikhaze, AK | 2 |
| Liakishev, AA | 1 |
| Kukharchuk, VV | 1 |
| Magil, A | 1 |
| Mikhin, VP | 1 |
| Ito, M | 1 |
| Suzuki, Y | 2 |
| Ishihara, M | 1 |
| Sia, YT | 1 |
| Lapointe, N | 1 |
| Parker, TG | 1 |
| Tsoporis, JN | 1 |
| Deschepper, CF | 1 |
| Calderone, A | 1 |
| Pourdjabbar, A | 1 |
| Jasmin, JF | 1 |
| Sarrazin, JF | 1 |
| Liu, P | 1 |
| Adam, A | 1 |
| Butany, J | 1 |
| Rouleau, JL | 1 |
8 other studies available for probucol and Chronic Illness
| Article | Year |
|---|---|
Discovery of novel phenolic antioxidants as inhibitors of vascular cell adhesion molecule-1 expression for use in chronic inflammatory diseases.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Antioxidants; Cells, Cul | 2004 |
Oral treatment with probucol in a pharmacological dose has no beneficial effects on mortality in chronic ischemic heart failure after large myocardial infarction in rats.
Topics: Administration, Oral; Animals; Antioxidants; Chronic Disease; Collagen; Heart Failure; Male; Myocard | 2007 |
[Effect of probucol on lipid metabolism and the clinical course of ischemic heart disease and arteriosclerosis obliterans of the vessels of the lower extremities].
Topics: Adult; Aged; Angina Pectoris; Arteriosclerosis Obliterans; Chronic Disease; Coronary Disease; Drug E | 1984 |
[The effect of long-term probucol intake on the lipoprotein cholesterol content and glutathione peroxidase activity in the blood of patients with coronary arteriosclerosis and hyperlipidemia].
Topics: Cholesterol, HDL; Cholesterol, LDL; Chronic Disease; Coronary Artery Disease; Drug Evaluation; Femal | 1993 |
Inhibition of progression of chronic puromycin aminonucleoside nephrosis by probucol, an antioxidant.
Topics: Animals; Antibiotics, Antineoplastic; Antioxidants; Chronic Disease; Disease Models, Animal; Disease | 1996 |
[The antioxidant probucol as a regulator of the intensity of free-radical lipid peroxidation processes in the blood of patients with coronary atherosclerosis].
Topics: Antioxidants; Chronic Disease; Coronary Artery Disease; Drug Evaluation; Female; Free Radicals; Glut | 1997 |
Anti-ulcer effects of antioxidants: effect of probucol.
Topics: Acetic Acid; Acute Disease; Animals; Anti-Ulcer Agents; Antioxidants; Chronic Disease; Cimetidine; D | 1998 |
Beneficial effects of long-term use of the antioxidant probucol in heart failure in the rat.
Topics: Animals; Antioxidants; Apoptosis; Atrial Natriuretic Factor; Chronic Disease; Disease Models, Animal | 2002 |